Keryx Biopharmaceuticals (NASDAQ:KERX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer.

Recs

0
Player Avatar pchop123 (79.61) Submitted: 4/8/2013 10:09:48 AM : Underperform Start Price: $7.21 KERX Score: -7.45

overpriced for the moment anyway

Featured Broker Partners


Advertisement